Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: a case-control study
- Author:
Adel Hussein ELDUMA
1
;
Mohammad Ali MANSOURNIA
;
Abbas Rahimi FOROUSHANI
;
Hamdan Mustafa Hamdan ALI
;
Asrar M A/Salam ELEGAIL
;
Asma ELSONY
;
Kourosh HOLAKOUIE-NAIENI
Author Information
- Publication Type:Original Article
- From:Epidemiology and Health 2019;41():e2019014-
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES:The emergence of multidrug-resistant tuberculosis (MDR-TB) is a major challenge for the global control of tuberculosis (TB). The aim of this study was to determine the risk factors associated with MDR-TB in Sudan.
METHODS:This case-control study was conducted from May 2017 to February 2019. Patients newly diagnosed with MDR-TB were selected as cases, and controls were selected from TB patients who responded to first-line anti-TB drugs. A questionnaire was designed and used to collect data from study participants. Logistic regression was used to evaluate associations between risk factors and MDR-TB infection. The best multivariate model was selected based on the likelihood ratio test.
RESULTS:A total of 430 cases and 860 controls were selected for this study. A history of previous TB treatment (adjusted odds ratio [aOR], 54.85; 95% confidence interval [CI], 30.48 to 98.69) was strongly associated with MDR-TB infection. We identified interruption of TB treatment (aOR, 7.62; 95% CI, 3.16 to 18.34), contact with MDR-TB patients (aOR, 5.40; 95% CI, 2.69 to 10.74), lower body weight (aOR, 0.89; 95% CI, 0.87 to 0.91), and water pipe smoking (aOR, 3.23; 95% CI, 1.73 to 6.04) as factors associated with MDR-TB infection.
CONCLUSIONS:Previous TB treatment and interruption of TB treatment were found to be the main predictors of MDR-TB. Additionally, this study found that contact with MDR-TB patients and water pipe smoking were associated with MDR-TB infection in Sudan. More efforts are required to decrease the rate of treatment interruption, to strengthen patients' adherence to treatment, and to reduce contact with MDR-TB patients.
